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The aim of this study was to determine whether tuberculosis (TB) treatment normalizes the lipid profile 
strongly affected by pulmonary TB. Serum levels of total cholesterol (TC), high density lipoprotein 
cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) were determined 
in 83 patients with pulmonary TB before and after treatment, and compared to results obtained from 100 
control subjects without TB. Before treatment, levels of TC (p<0.005), HDL-C (p<0.005) and LDL-C 
(p<0.005) were significantly lower in pulmonary TB patients than normal subjects. Unlike TC and LDL-C, 
HDL-C decrease was correlated (r = 0.96, p<0.05) with smear positivity extent (SPE). At the end of TB 
treatment, which lasted six months, TC (p<0.01) and HDL-C (p<0.005) levels were significantly increased 
than before treatment while LDL-C stayed relatively unchanged. The treatment significantly reduced the 
atherogenic indices TC/HDL-C (p<0.001), LDL-C/HDL-C (p<0.001) and log (TG/HDL-C) (p<0.001) levels. 
Our results show that tuberculosis treatment increases TC levels and normalizes HDL while reducing 
atherogenic indices to below levels of controls. 
 





Cholesterol has received much attention in recent years 
mainly because of its involvement in cardiovascular 
disease (Smith et al., 1992). Current recommendations 
for treatment are all geared towards reducing the serum 
cholesterol levels (Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults, 
2001). However, increasing evidence indicates a link 
between low blood cholesterol levels and a number of 
human diseases including tuberculosis (TB) (Perez-
Guzman et al., 2005; Deniz et al., 2007). Specifically, it is 
reported that hypocholesterolemia promotes the 
development of TB whereas hypercholesterolemia 
confers some protection against infection with 
Mycobacterium tuberculosis (MTB) (Wilson et al., 2003; 
Perez-Guzman et al., 2005). Despite the existence of 
such links between cholesterol and TB, it is not known to 
which extent the treatment of the disease affects lipid 
indicators in patients with TB. We formulate the hypo-
thesis that TB treatment is associated with restoration of 












This study was carried out as a pre-post test design study with a 
control group at Centre National Hospitalier de Pneumo-
Phtyisiologie Cotonou (CNHPP) which is a reference center for TB 
diagnosis and treatment in West Africa. From October 2011 to June 
2012, a total of 187 patients (72 females and 115 males) suffering 
from TB were admitted to CNHPP. Sputum and blood samples 
were systematically collected from all patients with clinical signs of 
pulmonary TB. Patients co-infected with MTB and human 
immunodeficiency virus, and those who underwent an incomplete 
TB treatment were excluded from the study. Furthermore, patients 
who were on antibiotic therapy or using any cholesterol lowering 
medication at the time of admission were also not included in the 
study. Eighty-three (83) out of 147 patients have met the criteria 
listed above and have been selected to participate in the study. All 
selected patients completed the treatment. One hundred (100) age- 
and sex-matched healthy subjects with no complaints and no 
known diseases were recruited at Hôpital Saint-Luc (Cotonou, 
Bénin) and enrolled as control group. This control group was tested 
negative upon TB diagnostic testing. Informed written consent was 
voluntarily obtained from each participant before entering the study 
and the local ethics board approved the study protocol. 
 
 
Diagnostic criteria and bacteriological examination 
 
On the basis of clinical signs, bacteriological diagnosis was 
requested by the physician for each patient. Two sputum samples 
were collected in two consecutive days in all patients. Sputum 
samples were examined by direct smear examination. Acid-fast 
mycobacteria (AFB) resist decolorization by acid-alcohol after 
primary staining owing to the high lipid (mycolic acid) content in 
their cell walls. The direct smear examination of sputum was carried 
out by auramine O stain. The technique consists of making a smear 
and drying it for 15-30 min, fixing it over the flame and staining for 
15 min. The slides were decolorated with 0.5% acid-alcohol, rinsed, 
counterstained with acridine orange for 2 min and air dried. The 
smears were examined under oil immersion lens of microscope 
(objective 40X, total magnification, X400). To determine the smear 
positivity extent (SPE), the number of AFB were counted by an 
experienced technician. The results are expressed as the number 
of AFB per number of fields (F) observed as follows: +/-: 1-18/50F, 
+: 4-36/10F, ++: 4-36/F, +++: >36/F.  
 
 
Measurement of biochemical parameters 
 
Blood from fasting patients was collected in a dry tube (without 
anticoagulant) before and after treatment in experimental subjects 
and once in control subjects. In the event that the dosage was 
postponed, the serum was aliquoted into 1.5 ml Eppendorf tubes 
and stored at -20°C until needed. Total cholesterol (TC) (Biolabo, 
France), high density lipoprotein cholesterol (HDL-C) (Biolabo, 
France) and triglycerides (TG) (ELITech Group, France) were 
assayed by enzymatic methods. Low density lipoprotein cholesterol 








The treatment was based on a combination of isoniazid (H), 
rifampicin (R), pyrazinamide (Z), ethambutol (E) and streptomycin 
(S) for a period of 6 months. It comprises an initial phase with a 
combination of ERHZ for two months, followed by a four month 
treatment of HR. In case of recurrence, the initial treatment 
comprised a two month treatment with ERHZS, followed by 1 month 






Data were evaluated by Student’s t-test using the SigmaPlot 
statistical analysis software (Systat Software, Inc. San Jose, CA, 
USA). Quantitative data are expressed as mean ± SEM. The null 





This study involved 83 TB patients as the experimental 
group and 100 normal subjects who had previously not 
been diagnosed or received treatment for TB as the 
control group. TB patients were aged between 12 and 62 
years with an average age of 32.37 ± 12.87 and included 
57 men (68.67%) and 26 women (31.33%). The control 
group consisted of 35 women (35.00%) and 65 men 
(65.00%). The age of the control group was between 17 
and 67 years with an average of 35.70 ± 12.48. There 
were no significant differences in age (p=0.078) between 
the two groups. 
Lipid parameters were measured in 83 experimental 
subjects suffering from TB and 100 control subjects. In 
TB patients, the same individuals were tested before 
treatment and at the end of treatment. Before treatment, 
TC (p<0.005), HDL-C (p<0.005) and LDL-C (p<0.005) 
levels were significantly lower in TB patients as com-
pared to normal subjects (Figure 1A). Triglycerides levels 
were unchanged between the two groups (Figure 1A). At 
the end of treatment, which lasted six months, the levels 
of TC remained significantly (p<0.01) lower in TB treated 
patients when compared to controls (Figure 1B). 
However, compared with the levels before treatment, TC 
levels increased significantly (p<0.01) (Figure 1C). TB 
treatment had not changed the levels of TG and LDL-C 
(Figures 1B and 1C). However, the levels of HDL-C were 
significantly increased after treatment compared to the 
control group (p<0.02) (Figure 1B) and with respect to 
non-treated TB patients (p<0.005) (Figure 1C). 
In order to determine whether changes in the levels of 
lipid parameters correlated with the extent of bacterial 
load in TB patients, we compared the levels of TC, HDL-  
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Figure 1. The mean levels of serum lipid parameters in treated and pre-treated tuberculosis patients. The mean levels 
of TC, TG, HDL-C and LDL-C of 83 tuberculosis patients prior to treatment (Pre-Treatment, Pre-T) (A) and at the end 
of treatment (Post-Treatment, Post-T) (B) were compared to that of 100 control patients. The values of lipid 
parameters in tuberculosis patients before (Pre-T) and after treatment (Post-T) were matched (C).  The values shown 




C and LDL-C to corresponding SPE before treatment. We 
did not observe any correlations between the levels of TC 
(Figure 2A) and LDL-C (Figure 2B) and SPE. However, 
we found a strong negative correlation (r = - 0.96, 
p<0.05) between HDL-C and SPE (Figure 2C). 
We calculated atherogenic indices in order to determine 
whether TB treatment affects these predictors of disease 
associated with dyslipidemia in TB patients. The results 
are summarized in Table 1. TC/HDL-C and LDL-C/HDL-C 
in TB patients were not significantly different from those 
in normal subjects. However, indices TC/HDL-C 
(p<0.001) and LDL-C/HDL-C (p<0.001) declined signifi-
cantly after six months of treatment compared to controls 
and to patients prior to treatment. Log (TG/HDL-C) is 
another index referred to as the atherogenic index of 
plasma and reflects the size of circulating LDL 
(Dobiasova and Frohlich, 2001). Log (TG/HDL-C) was 
significantly increased (p<0.002) in TB patients before 
treatment compared to controls and then fell significantly 
(p<0.001) after 6 months of treatment to levels lower than 
those in control subjects. We compared atherogenic 
indices with SPE in patients before treatment. TC/HDL-C 
ratio increased significantly (p<0.01) in patients in whom 
SPE was the highest (Figure 3A). Log (TG/HDL-C) 
increased with the smear positivity to reach its maximum 
level (p<0.05) in patients with the highest SPE (Figure 
3B). The index LDL-C/HDL-C did not vary significantly 





This study has shown that the level of TC was 
significantly lower in patients with TB. Similar results 
were reported elsewhere (Deniz et al., 2006 and 2007; 
Perez-Guzman et al., 2005). An adequate level of 
cholesterol is necessary for the proper functioning of the 
immune system against infection (Heiniger and Marshall, 
1982). Our results support the observation that the level 
of circulating TC decreases in severe infections 
(Gonzales and Sande, 2000). Perez-Guzman et al. 
(2005) have shown that a cholesterol-rich diet 
accelerates bacteriologic sterilization in patients with TB. 
We showed here that treatment  of TB during  six months 



















































































































Figure 2. Correlations between smear positivity extent scores and lipid parameters. The values of SPE scores were 
correlated to the levels of TC (A), LDL-C (B) and HDL-C (C) in tuberculosis patients before the beginning of anti-




Table 1.  Atherogenic indices variation in TB patients. 
 
Atherogenic index Controls (n=100) Pre-T (n=83) Post-T (n=83) 
TC/HDL-C 4.16 ± 0.18 4.55 ± 0.28 2.78 ± 0.11
a,a
 
LDL-C/HDL-C 2.77 ± 0.16 2.89 ± 0.23 1.49 ± 0.10
a,a
 
Log (TG/HDL-C)  0.19 ± 0.03 0.41 ± 0.04
d




Atherogenic indices were determined in TB patients pre- and post-treatment and in controls. The values are the mean ± SEM of 
individual index in 100 control participants and 83 TB patients prior to treatment (Pre-T) and post-treatment (Post-T). (
a
p<0.001 Post-T 
vs Control or Pre-T; 
b
p<0.05 Post-T vs Control; 
d




under a normal diet significantly raises the TC level. This 
indicates that hypocholesterolemia can be seen as a 
consequence of TB disease although it cannot be 
excluded as also being a factor contributing to the 
development of pulmonary TB (Pérez-Guzmán et al., 
2005). We have shown that there is no correlation 
between the bacillary load and TC variations. This 
suggests that the use of host cholesterol by MTB (Van 
der Geize et al., 2007) contributes little to the lower TC 
level in TB patients. 
We showed that HDL-C level decreased significantly in  
non-treated TB patients compared to controls, and 
increased significantly after treatment above the control 
levels. Our results also showed that HDL-C decrease 
was strongly correlated with SPE. In general, HDL-C 
catabolism increases during inflammation. Response to 
inflammation during the acute phase of TB is 
characterized by an over expression of proteins such as 
phospholipase A2 and circulating amyloid A (Tietge et al., 
2002) which stimulates HDL-C catabolism (Deniz et al., 
2006). It is therefore expected that the levels of HDL-C 

























Figure 3. Smear positivity extent variation with atherogenic indices. Changes in atherogenic indices are 
represented according to the results of SPE scores in TB patients before treatment. The results are 
presented as mean ± SEM of atherogenic indices value within SPE scores groups. (+p<0.01, *p<0.05), (+/-, 




shown by our results. LDL-C level decreased significantly 
in non-treated TB patients, but was not affected by the 
treatment. This suggests that the mechanism underlying 
LDL-C implication in MTB infection is different from HDL-
C. Oxidation followed by removal of LDL-C is reported 
during infection in Hamsters (Memon et al., 2000) but it is 
not known if this is the case in humans. 
Atherosclerosis and cardiovascular disease are 
common in clinical situations where dyslipidemia is 
present. We estimated the atherogenic indices TC/HDL-
C, LDL-C/HDL-C and log (TG/HDL-C) in order to 
determine whether TB and/or its treatment represent 
cardiovascular diseases risks. Our results showed that 
the atherogenic index of plasma log (TG/HDL-C) was 
significantly increased in TB patients without reaching the 
critical level synonymous of atherogenic risk (Maron, 
2000). We demonstrated that the atherogenic indices 
TC/HDL, LDL/HDL and log (TG/HDL) were significantly 
increased in patients with the highest SPE. We also 
showed that TB treatment induced significant reduction in 
all three atherogenic indices despite elevated total 
cholesterol. Improvement (decrease) in atherogenic 
indices reflects the increase in HDL-C after treatment as 
earlier reported by Deniz et al. (2006). 
Conclusion 
 
In this study, we showed that the recovery from TB is 
accompanied by normalization of lipid parameters such 
as cholesterol and HDL-C. Despite the rise of lipid 
parameter levels in TB treated patients, atherogenic 
indices were somewhat normal. Additional research is 
needed to more fully assess the link between TB 
treatment and levels of total cholesterol and its 
components in patients with pulmonary TB. It would be 
interesting to study the effectiveness of cholesterol 
supplement alone or in combination with antituberculosis 
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